90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03252847 (ClinicalTrials.gov) | July 14, 2017 | 1/8/2017 | Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) | An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2-.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR) | X-Linked Retinitis Pigmentosa | Genetic: AAV2/5-RPGR | MeiraGTx UK II Ltd | Syne Qua Non Limited;Bionical Emas | Completed | 5 Years | N/A | Male | 49 | Phase 1/Phase 2 | United States;United Kingdom |